
Hologic (HOLX) Stock Forecast & Price Target
Hologic (HOLX) Analyst Ratings
Bulls say
Hologic's diverse business segments, which include diagnostics, breast health, surgical, and skeletal health, are anticipated to contribute to organic revenue growth of 5-7% driven by strong procedure volumes and new product launches. Potential upside drivers such as improved revenue growth, higher operating margins, and strategic acquisitions could accelerate revenue growth to the high single digits (7-9%) while expanding operating margins and supporting 8-12% earnings growth. Additionally, Hologic's robust balance sheet and limited leverage enhance its financial stability and improve visibility on underlying business trends, positioning the company favorably for future growth.
Bears say
Hologic faces a negative outlook due to anticipated revenue growth slowing to low-single digits (1-4%), driven primarily by weakening performance in its Diagnostics and Breast Health segments. The company's historical stock performance has been lackluster, with only marginal returns over the past 3 and 5 years, coupled with sluggish demand in Breast Health exacerbated by a challenging global economic environment. Additionally, potential risks such as reduced hospital capital spending, market share loss, and obstacles from recent acquisitions further contribute to a pessimistic financial forecast for Hologic.
This aggregate rating is based on analysts' research of Hologic and is not a guaranteed prediction by Public.com or investment advice.
Hologic (HOLX) Analyst Forecast & Price Prediction
Start investing in Hologic (HOLX)
Order type
Buy in
Order amount
Est. shares
0 shares